Wenqin Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wenqin Yao has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Dongfeng Zhang
Department of Epidemiology and Health Statistics, Public Health College, Qingdao University, China
3 shared publications - Jia Luo
Department of Epidemiology and Health Statistics, the School of Public Health of Qingdao University, No. 308 Ningxia Road, Qingdao 266071, China
2 shared publications - Chunsheng Xu
Qingdao Municipal Center for Disease Control and Prevention, Qingdao, China
1 shared publication - Haiping Duan
Qingdao Center for Disease Control and Prevention, Qingdao, China
1 shared publication - Honghan Ge
Department of Epidemiology and Health Statistics, The School of Public Health of Qingdao University, No.308 Ningxia Road, Qingdao, 266021, Shandong, China
1 shared publication - Jing Sun
School of Public Health, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 17 July 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-12
Identification of key DNA methylation changes on fasting plasma glucose: a genome-wide DNA methylation analysis in Chinese monozygotic twins
Background: Elevated fasting plasma glucose (FPG) levels can increase morbidity and mortality even when it is below the diagnostic threshold of type 2 diabetes mellitus (T2DM). We conducted a genome-wide DNA methylation analysis to detect DNA methylation (DNAm) variants potentially related to FPG in Chinese monozygotic twins.Methods: Genome-wide DNA methylation profiling in whole blood of twins was performed using Reduced Representation Bisulfite Sequencing (RRBS), yielding 551,447 raw CpGs. Association between DNAm of single CpG and FPG was tested using a generalized estimation equation. Differentially methylated regions (DMRs) were identified usingcomb-Papproach. ICE FALCON method was utilized to perform the causal inference. Candidate CpGs were quantified and validated using Sequenom MassARRAY platform in a community population. Weighted gene co-expression network analysis (WGCNA) was conducted using gene expression data from twins.Results: The mean age of 52 twin pairs was 52 years (SD: 7). The relationship between DNAm of 142 CpGs and FPG reached the genome-wide significance level. Thirty-two DMRs within 24 genes were identified, includingTLCD1,MRPS31P5,CASZ1, andCXADRP3. The causal relationship of top CpGs mapped toTLCD1,MZF1,PTPRN2,SLC6A18,ASTN2,IQCA1,GRIN1, andPDE2Agenes with FPG were further identified using ICE FALCON method.Pathways potentially related to FPG were also identified, such as phospholipid-hydroperoxide glutathione peroxidase activity and mitogen-activated protein kinase p38 binding. Three CpGs mapped toSLC6A18gene were validated in a community population, with a hypermethylated direction in diabetic patients. The expression levels of 18 genes (includingSLC6A18andTLCD1) were positively correlated with FPG levels.Conclusions: We detect many DNAm variants that may be associated with FPG in whole blood, particularly the loci withinSLC6A18gene. Our findings provide important reference for the epigenetic regulation of elevated FPG levels and diabetes.
- 17 July 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-12
Open AccessIdentification of key DNA methylation changes on fasting plasma glucose: a genome-wide DNA methylation analysis in Chinese monozygotic twins
Background: Elevated fasting plasma glucose (FPG) levels can increase morbidity and mortality even when it is below the diagnostic threshold of type 2 diabetes mellitus (T2DM). We conducted a genome-wide DNA methylation analysis to detect DNA methylation (DNAm) variants potentially related to FPG in Chinese monozygotic twins.Methods: Genome-wide DNA methylation profiling in whole blood of twins was performed using Reduced Representation Bisulfite Sequencing (RRBS), yielding 551,447 raw CpGs. Association between DNAm of single CpG and FPG was tested using a generalized estimation equation. Differentially methylated regions (DMRs) were identified usingcomb-Papproach. ICE FALCON method was utilized to perform the causal inference. Candidate CpGs were quantified and validated using Sequenom MassARRAY platform in a community population. Weighted gene co-expression network analysis (WGCNA) was conducted using gene expression data from twins.Results: The mean age of 52 twin pairs was 52 years (SD: 7). The relationship between DNAm of 142 CpGs and FPG reached the genome-wide significance level. Thirty-two DMRs within 24 genes were identified, includingTLCD1,MRPS31P5,CASZ1, andCXADRP3. The causal relationship of top CpGs mapped toTLCD1,MZF1,PTPRN2,SLC6A18,ASTN2,IQCA1,GRIN1, andPDE2Agenes with FPG were further identified using ICE FALCON method.Pathways potentially related to FPG were also identified, such as phospholipid-hydroperoxide glutathione peroxidase activity and mitogen-activated protein kinase p38 binding. Three CpGs mapped toSLC6A18gene were validated in a community population, with a hypermethylated direction in diabetic patients. The expression levels of 18 genes (includingSLC6A18andTLCD1) were positively correlated with FPG levels.Conclusions: We detect many DNAm variants that may be associated with FPG in whole blood, particularly the loci withinSLC6A18gene. Our findings provide important reference for the epigenetic regulation of elevated FPG levels and diabetes.
- 26 September 2021
- Published by Springer Nature in Sleep and Breathing
- Vol. 26 (3) , 1409-1416
Insomnia symptoms are associated with an increased risk of type 2 diabetes mellitus among adults aged 50 and older
Purpose To evaluate the association of the different degrees of insomnia symptoms with subsequent incidence of type 2 diabetes mellitus (T2DM). Methods The data were extracted from Health and Retirement Study 2006–2014 waves. The association of insomnia symptoms with T2DM incidence was evaluated by the competing risk model with cumulative incidence function (death was considered a competing event) and Cox proportional hazard model with the Kaplan–Meier method. Population attributable fraction (PAF) was calculated. All analyses related to our study were conducted between November 2020 and January 2021. Results A total of 14,112 patients were included in this study, with an average follow-up of 6.4 years, and the incidence density was 17.9 per 1000 person-years. Insomnia symptoms were positively associated with T2DM incidence compared with those with no insomnia symptoms, regardless of competing risk model (≥ 1 symptoms: sub-distribution hazard ratio (SHR) 1.13; 95% confidence interval (CI) 1.02–1.26; P-trend = 0.012) and Cox proportional hazard model (≥ 1 symptoms: hazard ratio (HR) 1.13; 95% CI 1.02–1.26; P-trend = 0.013). The cumulative incidence function (Gray’s test, p < 0.001) and Kaplan–Meier estimate (log-rank test, p < 0.001) also presented this positive relationship. This positive association was more apparent in women and participants with ages from 50 to 65 years. The PAF was 4.1% with 95% CI (0.7–7.9%). Conclusions Insomnia symptoms may be an important risk factor for the development of T2DM, which is unbiased by the death competing risk. These findings suggest that management of sleep problems may be an important part of strategies to prevent T2DM.
- 26 September 2021
- Published by Springer Nature in Sleep and Breathing
- Vol. 26 (3) , 1409-1416
Insomnia symptoms are associated with an increased risk of type 2 diabetes mellitus among adults aged 50 and older
Purpose To evaluate the association of the different degrees of insomnia symptoms with subsequent incidence of type 2 diabetes mellitus (T2DM). Methods The data were extracted from Health and Retirement Study 2006–2014 waves. The association of insomnia symptoms with T2DM incidence was evaluated by the competing risk model with cumulative incidence function (death was considered a competing event) and Cox proportional hazard model with the Kaplan–Meier method. Population attributable fraction (PAF) was calculated. All analyses related to our study were conducted between November 2020 and January 2021. Results A total of 14,112 patients were included in this study, with an average follow-up of 6.4 years, and the incidence density was 17.9 per 1000 person-years. Insomnia symptoms were positively associated with T2DM incidence compared with those with no insomnia symptoms, regardless of competing risk model (≥ 1 symptoms: sub-distribution hazard ratio (SHR) 1.13; 95% confidence interval (CI) 1.02–1.26; P-trend = 0.012) and Cox proportional hazard model (≥ 1 symptoms: hazard ratio (HR) 1.13; 95% CI 1.02–1.26; P-trend = 0.013). The cumulative incidence function (Gray’s test, p < 0.001) and Kaplan–Meier estimate (log-rank test, p < 0.001) also presented this positive relationship. This positive association was more apparent in women and participants with ages from 50 to 65 years. The PAF was 4.1% with 95% CI (0.7–7.9%). Conclusions Insomnia symptoms may be an important risk factor for the development of T2DM, which is unbiased by the death competing risk. These findings suggest that management of sleep problems may be an important part of strategies to prevent T2DM.
- Open Access
Associations of Dietary ω-3, ω-6 Fatty Acids Consumption with Sleep Disorders and Sleep Duration among Adults
The relationship between ω-3 and ω-6 fatty acids consumption and sleep disorders or duration are controversial. Therefore, we used the data of the National Health and Nutrition Examination Survey 2007–2016 in this cross-sectional study to explore their relationships. ω-3 and ω-6 fatty acids consumption was assessed using two 24 h dietary recall interviews. Sleep disorders and sleep duration were based on self-reported data. Logistic regression models and restricted cubic spline analyses were used. Compared with tertile one, the odds ratios (ORs) and 95% confidence intervals (CIs) of sleep disorders for the second tertile of ω-6 fatty acid intake and the highest tertile of ω-6:ω-3 ratio were 1.30 (1.04–1.62) and 1.36 (1.08–1.70), respectively. Inverse U-shaped and linear dose–response relationships were observed between dietary ω-6 fatty acid intake and ω-6:ω-3 ratio and sleep disorders, respectively. In addition, ω-3 fatty acid consumption was adversely related to sleep disorders in men and the OR (95% CI) was 0.68 (0.49–0.95). Compared with normal sleep duration, ω-3 fatty acid consumption was negatively related to very short, short, and long sleep duration risk. The relative risk ratios (RRRs) were 0.53 (0.35–0.81), 0.79 (0.67–0.93), and 0.81 (068–0.98), respectively. The RRR of very short sleep for ω-6 fatty acid consumption was 0.57 (0.45–0.73). Our study indicates that ω-6 fatty acid consumption and the ω-6:ω-3 ratio are positively associated with the risk of sleep disorders, while the negative association between ω-3 fatty acids and sleep disorders may exist only in men. Furthermore, ω-3 and ω-6 fatty acid consumption are negatively related to the risk of non-normal sleep duration.
Open AccessAssociations of Dietary ω-3, ω-6 Fatty Acids Consumption with Sleep Disorders and Sleep Duration among Adults
The relationship between ω-3 and ω-6 fatty acids consumption and sleep disorders or duration are controversial. Therefore, we used the data of the National Health and Nutrition Examination Survey 2007–2016 in this cross-sectional study to explore their relationships. ω-3 and ω-6 fatty acids consumption was assessed using two 24 h dietary recall interviews. Sleep disorders and sleep duration were based on self-reported data. Logistic regression models and restricted cubic spline analyses were used. Compared with tertile one, the odds ratios (ORs) and 95% confidence intervals (CIs) of sleep disorders for the second tertile of ω-6 fatty acid intake and the highest tertile of ω-6:ω-3 ratio were 1.30 (1.04–1.62) and 1.36 (1.08–1.70), respectively. Inverse U-shaped and linear dose–response relationships were observed between dietary ω-6 fatty acid intake and ω-6:ω-3 ratio and sleep disorders, respectively. In addition, ω-3 fatty acid consumption was adversely related to sleep disorders in men and the OR (95% CI) was 0.68 (0.49–0.95). Compared with normal sleep duration, ω-3 fatty acid consumption was negatively related to very short, short, and long sleep duration risk. The relative risk ratios (RRRs) were 0.53 (0.35–0.81), 0.79 (0.67–0.93), and 0.81 (068–0.98), respectively. The RRR of very short sleep for ω-6 fatty acid consumption was 0.57 (0.45–0.73). Our study indicates that ω-6 fatty acid consumption and the ω-6:ω-3 ratio are positively associated with the risk of sleep disorders, while the negative association between ω-3 fatty acids and sleep disorders may exist only in men. Furthermore, ω-3 and ω-6 fatty acid consumption are negatively related to the risk of non-normal sleep duration.